TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Trial Between Insulin Glargine Plus Supplemental Glulisine (Apidra) Versus Sliding Scale Regular Insulin In Hospitalized Patients With Type 2 Diabetes
Brief Summary: High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. It is not known; however, what is the best insulin regimen in hospitalized patients. The use of repeated injections of regular insulin (known as sliding scale regimen) is one of the most commonly used insulin regimen for glucose control in hospitalized patients with diabetes. Recently, the combination of basal and rapid acting insulins has been shown to improve glucose control with lower rate of hypoglycemia (low blood sugar).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Insulin glulisine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Regular insulin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Regular insulin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Glargine insulin vs regular insulin; Assigned to Arm(s): N/A
C: Arm Label: IV insulin drip with target glucose 80 mg/dL - 130 mg/dL; Type: EXPERIMENTAL; Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL | Arm Label: Sub Q insulin to keep glucose less than 180 mg/dL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL | Intervention Type: DRUG; Name: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Assigned to Arm(s): IV insulin drip with target glucose 80 mg/dL - 130 mg/dL | Intervention Type: DRUG; Name: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL; Assigned to Arm(s): Sub Q insulin to keep glucose less than 180 mg/dL
D: Arm Label: sliding scale regular insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin | Arm Label: glargine insulin and glulisine insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: glargine basal insulin and glulisine prandial insulin | Intervention Type: DRUG; Name: sliding scale regular insulin; Assigned to Arm(s): sliding scale regular insulin | Intervention Type: DRUG; Name: glargine basal insulin and glulisine prandial insulin; Assigned to Arm(s): glargine insulin and glulisine insulin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease
Brief Summary: The relationship between elevated phosphorus levels and morbidity and mortality in patients with chronic kidney disease (CKD) is well recognized, and dietary phosphorus restriction is a mainstay of phosphate management. Current study is an effort to test the effect of a web-based nutritional educational intervention, Kidney School(KS), to improve phosphorous knowledge and control phosphorous intake in CKD patients.


Options:
A: Arm Label: usual care plus Internet-based nutrition module; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based nutrition module along with usual care | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: Internet-based nutrition module along with usual care; Assigned to Arm(s): usual care plus Internet-based nutrition module | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): usual care
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention
C: Arm Label: ATSM + Health Coach and CKD Registry; Type: EXPERIMENTAL; Interventions: Behavioral: CKD Registry, Behavioral: ATSM + Health Coach | Arm Label: CKD Registry; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CKD Registry | Arm Label: ATSM + Health Coach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM + Health Coach | Arm Label: Usual Care (no interventions); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: CKD Registry; Assigned to Arm(s): ATSM + Health Coach and CKD Registry, CKD Registry | Intervention Type: BEHAVIORAL; Name: ATSM + Health Coach; Assigned to Arm(s): ATSM + Health Coach, ATSM + Health Coach and CKD Registry | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care (no interventions)
D: Arm Label: Computer Use; Type: EXPERIMENTAL; Interventions: Other: Computer Use | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Computer Use; Assigned to Arm(s): Computer Use

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease
Brief Summary: The relationship between elevated phosphorus levels and morbidity and mortality in patients with chronic kidney disease (CKD) is well recognized, and dietary phosphorus restriction is a mainstay of phosphate management. Current study is an effort to test the effect of a web-based nutritional educational intervention, Kidney School(KS), to improve phosphorous knowledge and control phosphorous intake in CKD patients.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Intervention, Behavioral: Placebo | Intervention Type: BEHAVIORAL; Name: Educational Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Control, Intervention
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TMITT; Type: ACTIVE_COMPARATOR; Interventions: Other: Transplant Medication Information Teaching Tool | Intervention Type: OTHER; Name: Transplant Medication Information Teaching Tool; Assigned to Arm(s): TMITT
C: Arm Label: TALK Plus; Type: EXPERIMENTAL; Interventions: Behavioral: TALK PLUS | Arm Label: TALK Standard; Type: EXPERIMENTAL; Interventions: Behavioral: TALK Standard | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: TALK PLUS; Assigned to Arm(s): TALK Plus | Intervention Type: BEHAVIORAL; Name: TALK Standard; Assigned to Arm(s): TALK Standard | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: usual care plus Internet-based nutrition module; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based nutrition module along with usual care | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: Internet-based nutrition module along with usual care; Assigned to Arm(s): usual care plus Internet-based nutrition module | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve and Early Versus Delayed Analysis
Brief Summary: The purpose of this study is to look at two different treatments during a cardiac arrest that occurs outside of the hospital and whether either or both treatments will increase the number of people who live to hospital discharge. A cardiac arrest is when the heart stops pumping blood to the body.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Impedance Threshold Device (ITD) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham ITD | Arm Label: 3; Type: OTHER; Interventions: Other: Analyze early | Arm Label: 4; Type: OTHER; Interventions: Other: Analyze later | Intervention Type: DEVICE; Name: Impedance Threshold Device (ITD); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham ITD; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Analyze early; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Analyze later; Assigned to Arm(s): 4
B: Arm Label: 1:Mechanical CPR with LUCAS; Type: EXPERIMENTAL; Interventions: Device: LUCAS | Arm Label: 2 Manual CPR; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional manual resuscitation method | Intervention Type: DEVICE; Name: LUCAS; Assigned to Arm(s): 1:Mechanical CPR with LUCAS | Intervention Type: OTHER; Name: Conventional manual resuscitation method; Assigned to Arm(s): 2 Manual CPR
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual CPR | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual CPR; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard cardiopulmonary resuscitation (S-CPR) | Intervention Type: DEVICE; Name: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard cardiopulmonary resuscitation (S-CPR); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation Program in Patients With Chronic Low Back Pain and Degenerative Disc. A Prospective Randomized Clinical Multicentre Trial.
Brief Summary: Surgical methods offered to patients with chronic low back pain are controversial. In addition, new and expensive treatment methods like total disc replacemet (TDR) are a challenge for the health care services. At present, ongoing randomized studies in both Europe and USA are comparing TDR to fusion. However, to our knowledge, no randomized trials have compared TDR to non-surgical treatment. The aim of the present study is to evaluate the effect of a comprehensive and structured non-surgical treatment with TDR surgery in patients with chronic low back pain and localized degenerative disc changes.

Main hypothesis: There is no difference in treatment effect between surgery with lumbar total disc prosthesis and a multidisciplinary rehabilitation program measured by Oswestry Disability Index after 1 and 2 years.

Secondary hypothesis: There is no difference in cost - effectiveness between surgery with lumbar disc prosthesis and a multidisciplinary rehabilitation program after 1 and 2 years.


Options:
A: Intervention Type: DEVICE; Name: Total Disc Prosthesis; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Multidisciplinary rehabilitation program; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
C: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard physical therapy | Arm Label: Graded exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Graded exercise | Arm Label: Graded exposure; Type: EXPERIMENTAL; Interventions: Other: Graded exposure | Intervention Type: BEHAVIORAL; Name: Standard physical therapy; Assigned to Arm(s): Standard | Intervention Type: BEHAVIORAL; Name: Graded exercise; Assigned to Arm(s): Graded exercise | Intervention Type: OTHER; Name: Graded exposure; Assigned to Arm(s): Graded exposure
D: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation Program in Patients With Chronic Low Back Pain and Degenerative Disc. A Prospective Randomized Clinical Multicentre Trial.
Brief Summary: Surgical methods offered to patients with chronic low back pain are controversial. In addition, new and expensive treatment methods like total disc replacemet (TDR) are a challenge for the health care services. At present, ongoing randomized studies in both Europe and USA are comparing TDR to fusion. However, to our knowledge, no randomized trials have compared TDR to non-surgical treatment. The aim of the present study is to evaluate the effect of a comprehensive and structured non-surgical treatment with TDR surgery in patients with chronic low back pain and localized degenerative disc changes.

Main hypothesis: There is no difference in treatment effect between surgery with lumbar total disc prosthesis and a multidisciplinary rehabilitation program measured by Oswestry Disability Index after 1 and 2 years.

Secondary hypothesis: There is no difference in cost - effectiveness between surgery with lumbar disc prosthesis and a multidisciplinary rehabilitation program after 1 and 2 years.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Mod. functional restoration-Individ. dynamic back-muscle; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Total Disc Prosthesis; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Multidisciplinary rehabilitation program; Assigned to Arm(s): N/A
D: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Surgical Procedures in Vulvar and Vaginal Dysplasias
Brief Summary: 1. To compare the recurrence rate between the use of laser vaporization and ultrasonic surgical aspiration in the treatment of vulvar and vaginal dysplasias
2. To compare healing related complications, post-operative pain, and scarring between the two procedures.


Options:
A: Arm Label: Cidofovir; Type: EXPERIMENTAL; Interventions: Drug: cidofovir, Genetic: DNA methylation analysis, Genetic: gene expression analysis, Genetic: polymerase chain reaction, Procedure: biopsy, Procedure: histopathologic examination | Intervention Type: DRUG; Name: cidofovir; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: histopathologic examination; Assigned to Arm(s): Cidofovir
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3
C: Intervention Type: PROCEDURE; Name: CO2 laser surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ultrasonic surgical aspiration; Assigned to Arm(s): N/A
D: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Measures
Brief Summary: The purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension


Options:
A: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
C: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Intervention Type: BEHAVIORAL; Name: Set of supportive tools/measures vs. standard care; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis
Brief Summary: This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
B: Arm Label: Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: QM; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Q2W, QM
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Arm Label: CinnaPoietin®; Type: EXPERIMENTAL; Interventions: Drug: CinnaPoietin®, Drug: Nephrovit, Drug: Vitamin B12 Injection | Arm Label: Eprex®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eprex®, Drug: Nephrovit, Drug: Vitamin B12 Injection | Intervention Type: DRUG; Name: CinnaPoietin®; Assigned to Arm(s): CinnaPoietin® | Intervention Type: DRUG; Name: Eprex®; Assigned to Arm(s): Eprex® | Intervention Type: DRUG; Name: Nephrovit; Assigned to Arm(s): CinnaPoietin®, Eprex® | Intervention Type: DRUG; Name: Vitamin B12 Injection; Assigned to Arm(s): CinnaPoietin®, Eprex®

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis
Brief Summary: This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1

Answer: C